Discover why 22nd Century’s plant‑biotech hype has collapsed—low cap, flat trading, and zero product progress—revealing a cautionary tale for investors.
22nd Century Group Inc. stock drops 9.5% as biotech firm faces liquidity woes; learn why the plant‑breeding company’s price is slumping amid market volatility.